PerkinElmer, Waltham, Mass., has entered into an agreement to acquire Nexcelom Bioscience for $260 million in cash. The transaction is expected to close during the second quarter of 2021.
Headquartered in Lawrence, Mass., Nexcelom is a global provider of automated cell counting instruments; image cytometry workstations; assays; and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO cell counting standards and aid in the development of cell and gene and immuno-oncology therapies, virology drugs, and vaccines.
“We are looking forward to bringing Nexcelom’s expertise and technologies in drug development together with our passion and solutions for drug discovery,” says Prahlad Singh, president and chief executive officer of PerkinElmer. “This combination will expand our efforts to help academic, government, and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies.”
Peter Li, PhD, president and chief executive officer of Nexcelom, adds, “Our team is very excited to be joining forces with PerkinElmer to help scientists resolve some of today’s most pressing health challenges through modernizing cell-based assays using the most advanced cell models. Our organization has a deep commitment to innovation, and we are looking forward to continuing to grow our technology and customer footprint in combination with PerkinElmer’s strong global presence and infrastructure.”